Pharmacological insights into modified citrus pectin: A promising therapeutic potential with anticancer effect | ||
| International Journal of Applied Biochemistry and Molecular Biology | ||
| Volume 2, Issue 2, June 2025, Pages 55-86 PDF (528.06 K) | ||
| Document Type: Review Article | ||
| DOI: 10.21608/ijabmb.2025.386020.1013 | ||
| Authors | ||
| Randa Ismail* ; Heba A. Habib; Aliaa F. Anter; Gehan H. Heeba | ||
| Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, El-Minia, Egypt | ||
| Abstract | ||
| Modified citrus pectin (MCP) is a naturally soluble dietary fiber derived from citrus pectin that inhibits galectin-3 (Gal-3), a proinflammatory, profibrotic, and pro-metastatic regulatory protein. Interestingly, the anticancer activity of MCP against multiple cancers, such as colon, prostate, urinary bladder, hemangiosarcoma, and breast cancers, has been demonstrated. It could be attributed to its inhibitory effect on cancer cell growth, prevention of metastasis, and induction of cancer cell apoptosis. In addition, MCP presented protective effects against organ damage in different disease models, including cardioprotective, neuroprotective, renoprotective, and hepatoprotective effects. This could be ascribed to its antioxidant, anti-inflammatory, anti-apoptotic, and antifibrotic effects. Further, immunomodulatory, detoxifying, antimicrobial, and chondroprotective effects have also been demonstrated with MCP. It is available in the market as a regarded safe dietary supplement due to its health-promoting effects. This review involves the interplay between cancer, Gal-3, and MCP, as well as the beneficial impacts of MCP in several models of organ damage. | ||
| Keywords | ||
| modified citrus pectin; galectin-3; cancer; organ damage | ||
|
Statistics Article View: 146 PDF Download: 112 |
||
